By Nate Wolf
Insulet stock was climbing Friday after the insulin pump maker's results beat earnings expectations and raised its forecast for the rest of 2025.
The company reported first-quarter earnings of $1.02 a share and $569 million in revenue, beating Wall Street's consensus estimates of 79 cents a share and $543 million, respectively.
Insulet was the best performer in the S&P 500 on Friday, with its shares up 17% to $300.01.
In Thursday's earnings release, management boosted guidance for full-year revenue growth to a range of 19% to 22%, up from a previous forecast of 16% to 20%.
"Our first-quarter results showcase the strong execution and dedication of the Insulet team," said CEO Ashley McEvoy. "I see a path to scale the Company from an emerging diabetes leader to a durable growth engine."
Insulet stock has soared 81% over the last 12 months, buoyed by the Food and Drug Administration's approval of the company's Omnipod 5 Insulin System for adults with Type 2 diabetes last August.
Wall Street sees potential for the stock to rise even further.
Analysts at Oppenheimer maintained their Outperform rating and bumped their price target to $324 from $312, citing the launch of Omnipod 5 in international markets this year and the product's continued rollout in the U.S.
Jayson Bedford and Elaine Cui of Raymond James also reiterated their Outperform rating and $328 price target, calling Insulet "worthy of a higher stock price."
Write to Nate Wolf at nate.wolf@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
May 09, 2025 10:11 ET (14:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。